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A B S T R A C T
In this study, the efficacy of dietary anthocyanins (ACs) on indices of oxidative stress and antioxidative capacity
was evaluated through a meta-analytical approach. meta-analysis of 23 trials indicated that ACs significantly
reduced the levels of malondialdehyde (MDA; −0.41, 95% CI: −0.62 to −0.21, P < 0.001), oxidized low-
density lipoprotein (Ox-LDL; −0.27, 95% CI: −0.55 to 0.02, P = 0.064), and isoprostane (−0.57, 95% CI:
−0.78 to−0.36, P < 0.001) while significantly increased the level of total antioxidative capacity (TAC; 0.32,
95% CI: 0.08 to 0.55, P = 0.008) and activity of superoxide dismutase (SOD; 0.29, 95% CI: 0.07 to 0.51,
P = 0.010) and glutathione peroxidase (GPx; 0.59, 95% CI: 0.19 to 1.0, P = 0.004). Compared to healthy
subjects, ACs were more useful for unhealthy subjects because of the significant decrease in MDA, Ox-LDL, and
isoprostane levels; and significant increase in TAC level and SOD activity. The overall results indicate that
dietary ACs alleviate oxidative stress and enhance antioxidative capacity in the subjects.
1. Introduction
Oxidative stress indicates a condition in which the production of
reactive oxygen species (ROS) is beyond the capability of the anti-
oxidative defense system to destroy them. Elevated levels of ROS da-
mage to main cellular components such as lipids, proteins, and DNA,
can lead to cytotoxic, genotoxic, and carcinogenic effects (Pisoschi &
Pop, 2015; Sies, 1991). On the other hand, ROS activate nuclear factor
κB pathways and cause inflammation via increasing the gene expression
of inflammatory factors (Serasanambati & Chilakapati, 2016). Evidence
from previous surveys demonstrates that oxidative stress is associated
with the pathogenesis of several human degenerative diseases such as
diabetes, cancers, and cardiovascular diseases (Rani, Deep, Singh, Palle,
& Yadav, 2016).
The enzymes such as catalase, glutathione peroxidase (GPx), and
superoxide dismutase (SOD), and the molecules like reduced glu-
tathione are considered as natural endogenous antioxidative defense
system against oxidative stress. In addition, entrance of natural anti-
oxidants, like some vitamins and polyphenols, into the body through
consumption of fruits and vegetables can be effective in preventing the
harmful effects of oxidative stress (Jafari, 2016; Pisoschi & Pop, 2015).
Previous studies showed that intake of dietary natural antioxidants
improved the activity of endogenous enzymes involved in antioxidative
defense system against oxidative stress (Jafari, 2016; Mathew, Tiwari,
& Jatawa, 2011; Pisoschi & Pop, 2015).
Anthocyanins (ACs), a subgroup of polyphenolic compounds, are
natural pigments that contribute to formation of red to blue color in
various vegetables and fruits such as berries, black currant, and purple
sweet potato. The in vitro and in vivo studies identified ACs as powerful
antioxidative compounds to prevent the progression of several chronic
degenerative diseases (Kirakosyan et al., 2018; Norberto et al., 2013;
Pojer, Mattivi, Johnson, & Stockley, 2013).
Human clinical trials demonstrated that intake of dietary ACs or
anthocyanin-rich foodstuffs have several health benefits such as pro-
tection against cardiovascular diseases (Alvarez-Suarez et al., 2014),
alleviation of inflammation in subjects with metabolic syndrome (Nair,
Mariappan, Stull, & Francis, 2017), weight reduction in overweight/
obese subjects (Cardile, Graziano, & Venditti, 2015), improvement of
glycemic status in diabetics (Gorji et al., 2014), protection against bone
loss in postmenopausal smokers (Kaume, Gbur, DiBrezzo, Howard, &
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Devareddy, 2014), alleviation of lipid profile in subjects with polygenic
dyslipidemia (Hajifaraji et al., 2018), and prevention of obesity in
healthy subjects (Tucakovic et al., 2018).
The efficacy of dietary ACs on indices of oxidative stress and anti-
oxidative capacity is investigated in several human clinical trials, but
different results have been reported. In this research, we evaluated the
effect of pure ACs or ACs-rich extract/powder on levels of mal-
ondialdehyde (MDA), oxidized low-density lipoprotein (Ox-LDL), iso-
prostane, total antioxidative capacity (TAC), and activities of SOD and
GPx through a meta-analytical approach.
2. Methods
2.1. Search strategy
Four biomedical literature databases including PubMed, Scopus, ISI
Web of Science, and MagIran were searched for published trials up to
10 February 2020. The used keywords were: anthocyanin, anthocya-
nins, anthocyanin-rich, oxidative stress, antioxidant capacity, anti-
oxidative capacity, antioxidant defense, antioxidative defense, lipid
oxidation, lipid peroxidation, malondialdehyde, MDA, oxidized low-
density lipoprotein, Ox-LDL, isoprostane, superoxide dismutase, SOD,
glutathione peroxidase, and GPx.
Manual searching was carried out on the reference list of selected
trials and published reviews to avoid losing the studies. The search was
limited to clinical trials of human subjects and performed by 2 authors
(ES and AAF).
2.2. Study eligibility
The studies were selected for this meta-analysis if they met the
following criteria: (i) the parallel or crossover randomized controlled
trials (RCTs) on adult subjects (age ≥ 18 y) in which dietary ACs were
provided for the intervention group; (ii) RCTs used placebo in control
group or the difference between the groups was only intake of ACs; (iii)
the duration of intervention was at least 2 weeks; (iv) the anthocyanin
intake was reported or could be calculated for the intervention group;
(v) the outcomes provided adequate statistics on baseline and endpoint
values of oxidative stress or antioxidative capacity markers including
MDA, Ox-LDL, isoprostane, TAC, SOD, or GPx.
2.3. Data extraction
The following data were extracted from the selected trials: (i) study
characteristics including first author’s last name, publication year, daily
dose and form of ACs, study design, duration of intervention, and
sample size of control and intervention group; (ii) participant in-
formation including country of origin, average age, and health status;
(iii) study outcomes including levels of MDA, Ox-LDL, isoprostane, TAC,
SOD, or GPx. The GetData Graph Digitizer software version 2.24 was
employed to extract data from the plots.
2.4. Quality evaluation of trials and overall estimates
The quality of each eligible trial was evaluated by Cochrane
Collaboration tool including the risk of bias domains such as random
sequence generation (RSG), allocation concealment (AC), blinding of
participants and personnel (BPP), blinding of outcome assessment
(BOA), incomplete outcome data (IOD), selective outcome reporting
(SOR), and other sources of bias including bias of study design, trial
stopped early, extreme baseline imbalance, and fraudulent trial. Each
mentioned domain was graded as low, unclear, or high risk of bias
(Higgins et al., 2019). The RCTs quality were categorized as “Good”,
“Fair”, or “Low” as described in our previous study (Fallah, Sarmast,
Fatehi, & Jafari, 2020).
The NutriGrade scoring system was used to evaluate the overall
estimate quality of each marker (Schwingshackl et al., 2016). This
scoring system comprises several items such as risk of bias, precision,
heterogeneity, directness, publication bias, funding bias, and study
design. The overall estimate of each marker ranked from 0 to 10. The
ranks of 0–3.99, 4–5.99, 6–7.99, and 8–10 were regarded as very low,
low, moderate, and high quality, respectively.
2.5. Statistical analyses
The effect size for MDA, Ox-LDL, isoprostane, TAC, SOD, or GPx in
each trial was calculated as bias corrected standardized mean difference
(Hedges’ g method) and its 95% confidence interval (CI) (Askari, Iraj,
Salehi-Abargouei, Fallah, & Jafari, 2015). Because the selected trials
were performed in various settings, random effects model was used to
compute the summary effect for the effect sizes (DerSimonian & Laird,
1986; Fallah et al., 2018). The variables including duration of trials,
dosages of ACs, and health status of participants were used to conduct
subgroup analyses. The inter-study heterogeneity was explored by Co-
chrane Q test at P ≤ 0.050 (Higgins et al., 2019). The degree of inter-
study heterogeneity was quantified by I-squared (I2) index; and I2 va-
lues of 25, 50, and 75 were considered as low, moderate, and high
estimates, respectively (Higgins, Thompson, Deeks, & Altman, 2003).
The sources of inter-study heterogeneity were assessed by conducting
influence analysis (Jafari, Rostampour, Fallah, & Hesami, 2017). The
publication bias was analyzed by Begg and Mazumdar adjusted rank
correlation test (Begg & Mazumdar, 1994; Jafari, Feizi, Askari, & Fallah,
2015) and Egger’s regression asymmetry test (Egger, Smith, Schneider,
& Minder, 1997; Jafari, Fallah, & Barani, 2016). The analyses were
carried out using Stata software version 14.2 (Stata Corporation, Col-
lege Station, TX) and P ≤ 0.050 was regarded as significant value.
3. Results
3.1. Search results
The literature search yielded 2533 records, of which 1231 were
duplicate. After excluding duplicates, the remaining records were as-
sessed and 1174 records were removed because of their irrelevancy to
the topic. After further screening, 23 studies (Arevström et al., 2019;
Basu et al., 2010, 2014; Broncel et al., 2010; Chew et al., 2019;
Davinelli, Bertoglio, Zarrelli, Pina, & Scapagnini, 2015; Espinosa-
Moncada et al., 2018; Guo et al., 2020; Johnson et al., 2017; Kim et al.,
2018; Li, Zhang, Liu, Sun, & Xia, 2015; Maeda-Yamamoto et al., 2018;
Moazen et al., 2013; Naruszewicz, Łaniewska, Millo, & Dłużniewski,
2007; Nilsson, Salo, Plaza, & Björck, 2017; Park et al., 2015;
Puupponen-Pimiä et al., 2013; Riso et al., 2013; Riva et al., 2017;
Soltani, Hakimi, Asgary, Ghanadian, Keshvari, & Sarrafzadegan, 2014;
Terrazas et al., 2020; Vidlar et al., 2010; Xie et al., 2017) comparing
intervention group (administered dietary ACs) with control group were
selected to conduct meta-analyses. The process is presented in Fig. 1.
3.2. Study specifications
The specifications of 23 trials, enrolling 1044 subjects, performed in
Iran, USA, Poland, Italy, China, Korea, Japan, Czech Republic, Finland,
Brazil, Colombia, and Sweden are summarized in Table 1. The ad-
ministrated dose of ACs was from 1.7 to 1230 mg/day; and the dietary
intervention lasted from 2 to 26 weeks. The participants were healthy
in 8 trials (Chew et al., 2019; Guo et al., 2020; Maeda-Yamamoto et al.,
2018; Nilsson et al., 2017; Park et al., 2015; Riso et al., 2013; Riva
et al., 2017; Terrazas et al., 2020), individuals with metabolic syn-
drome in 5 trials (Basu et al., 2010; Broncel et al., 2010; Espinosa-
Moncada et al., 2018; Kim et al., 2018; Puupponen-Pimiä et al., 2013),
diabetic in 2 trials (Li et al., 2015; Moazen et al., 2013), obese/over-
weight in 2 trials (Basu et al., 2014; Davinelli et al., 2015), individuals
with post myocardial infarction in 2 trials (Arevström et al., 2019;
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Naruszewicz et al., 2007), individuals with lower urinary tract symp-
toms in 1 trial (Vidlar et al., 2010), former smokers in 1 trial (Xie et al.,
2017), hypertensives in 1 trial (Johnson et al., 2017), and hyperlipi-
demic in 1 trial (Soltani et al., 2014).
3.3. Quality evaluation of trials and overall estimates
Quality appraisal of trials based on Cochrane criteria are shown in
Table 2. Despite the fact that all the eligible trials were randomised,
explanation for RSG and AC were missing in 9 (Basu et al., 2010, 2014;
Broncel et al., 2010; Davinelli et al., 2015; Li et al., 2015; Naruszewicz
et al., 2007; Nilsson et al., 2017; Park et al., 2015; Riva et al., 2017) and
13 (Arevström et al., 2019; Basu et al., 2010, 2014; Espinosa-Moncada
et al., 2018; Johnson et al., 2017; Li et al., 2015; Moazen et al., 2013;
Naruszewicz et al., 2007; Nilsson et al., 2017; Park et al., 2015;
Puupponen-Pimiä et al., 2013; Riva et al., 2017; Vidlar et al., 2010)
trials, respectively. In addition, 1 trial (Xie et al., 2017) for RSG and 2
trials (Broncel et al., 2010; Xie et al., 2017) for AC had high risk of bias.
Four trials (Basu et al., 2010; Broncel et al., 2010; Naruszewicz et al.,
2007; Xie et al., 2017) had high risk of bias for BPP, whereas no trial
was high risk of bias based on BOA. None of the trials was high risk of
bias for IOD, SOR, and other sources of bias including bias of study
design, extreme baseline imbalance, trial stopped early, and fraudulent
trial. From 23 eligible trials, 20 trials (Arevström et al., 2019; Basu
et al., 2014; Chew et al., 2019; Davinelli et al., 2015; Espinosa-Moncada
et al., 2018; Guo et al., 2020; Johnson et al., 2017; Kim et al., 2018; Li
et al., 2015; Maeda-Yamamoto et al., 2018; Moazen et al., 2013; Nilsson
et al., 2017; Park et al., 2015; Puupponen-Pimiä et al., 2013; Riso et al.,
2013; Riva et al., 2017; Soltani et al., 2014; Terrazas et al., 2020; Vidlar
et al., 2010; Xie et al., 2017) were classified as “Good”, 1 trial
(Naruszewicz et al., 2007) as “Fair”, and 2 trials (Basu et al., 2010;
Broncel et al., 2010) as “Low”.
The meta-analysis quality was high for MDA. This fact points out
that further survey presumably will not affect the confidence in the
estimation of overall effect. Also, the meta-analysis quality was mod-
erate for Ox-LDL, isoprostane, TAC, SOD, and GPx (Table 3), indicating
that further survey might change the confidence in the estimation of
overall effects.
3.4. Effect of ACs on MDA
The overall effect from 18 trials, with 635 subjects, indicated sig-
nificant reduction in MDA level following administration of dietary ACs
(Supplementary Data, Fig. S1: −0.32, 95% CI: −0.54 to −0.11,
P = 0.003); however, inter-trial heterogeneity was high based on I2
statistic (46.7%) and Cochrane Q test (P = 0.015). The influence
analysis showed that studies of Maeda-Yamamoto et al. (2018) and Guo
et al. (2020; anthocyanin dose of 20 mg/day) were the source of het-
erogeneity. After omission of the mentioned studies, the inter-trial
heterogeneity was reduced (I2 = 28.8%, Cochrane Q test P = 0.134);
and the overall estimate showed significant reduction in MDA level
following ACs supplementation (Fig. 2: −0.41, 95% CI: −0.62 to
−0.21, P < 0.001).
Fig. 1. PRISMA flow diagram of study identification, inclusion, and exclusion.
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3.5. Effect of ACs on Ox-LDL
Seven studies, with 352 participants, explored the efficacy of ACs
supplementation on level of Ox-LDL. The overall estimate showed
marginally significant reduction in Ox-LDL level (Supplementary Data,
Fig. S2: −0.50, 95% CI: −1.0 to 0.01, P = 0.054). Heterogeneity
among the studies was high according to the results of I2 statistic
(79.4%) and Cochrane Q test (P < 0.01). Influence analysis revealed
that the study of Davinelli et al. (2015) was the source of heterogeneity.
After exclusion of this study, the heterogeneity was reduced
(I2 = 29.7%, Cochrane Q test P = 0.201), and random-effects analysis
showed a marginal significant reduction of Ox-LDL after consuming ACs
(Fig. 2: −0.27, 95% CI: −0.55 to 0.02, P = 0.064).
3.6. Effect of ACs on isoprostane
There were 449 participants in 13 trials in which the efficacy of ACs
supplementation on isoprostane level was assessed. The overall analysis
demonstrated significant reduction of isoprostane level following ACs
administration (Fig. 2: −0.57, 95% CI: −0.78 to −0.36, P < 0.001).
No evidence of inter-trial heterogeneity was found by I2 statistic (0%)
and Cochrane Q test (P = 0.604).
3.7. Effect of ACs on TAC
Effect of ACs supplementation on TAC was examined in 11 studies
with 325 subjects; and the results showed significant increase in TAC
level (Fig. 3: 0.32, 95% CI: 0.08 to 0.55, P = 0.008). Heterogeneity
among the studies was low according to I2 statistic (18.8%) and Co-
chrane Q test (P = 0.264).
3.8. Effect of ACs on SOD
Eight studies with 407 participants involved in the meta-analysis
had data on the effect of ACs on SOD activity; and the overall estimate
demonstrated significant increase in SOD activity (Supplementary Data,
Fig. S3: 0.37, 95% CI: 0.12 to 0.62, P = 0.004). Heterogeneity among
the studies was moderate according to I2 statistic (30.4%) and Cochrane
Q test (P = 0.185). Influence analysis revealed that study of Broncel
et al. (2010) was the source of heterogeneity. After omitting the men-
tioned study, the heterogeneity was clearly reduced (I2 = 0.0%, Co-
chrane Q test P = 0.630), and significant increase in SOD activity was
obtained (Fig. 4: 0.29, 95% CI: 0.07 to 0.51, P = 0.010).
3.9. Effect of ACs on GPx
Seven trials, with 331 subjects, evaluated the effect of dietary ACs
on GPx activity, and the overall estimate showed significant increase in
GPx activity (Supplementary Data, Fig. S4: 0.45, 95% CI: 0.0 to 0.89,
P = 0.048). According to the I2 statistic (55%) and Cochrane Q test
(P = 0.038), inter-trial heterogeneity was high. Influence analysis
showed that the study of Riso et al. (2013) was the source of hetero-
geneity. After exclusion of this study, the inter-trial heterogeneity was
reduced (I2 = 37%, Cochrane Q test P = 0.160); and overall estimate
showed significant increase in GPx activity following ACs administra-
tion (Fig. 4: 0.59, 95% CI: 0.19 to 1.0, P = 0.004).
3.10. Subgroup analyses
Subgroup analysis based on intervention duration showed that ACs
supplementation for less than 8 weeks decreased the serum levels of
MDA and isoprostane and increased TCA level and GPx activity, while
intervention duration≥8 weeks increased activities of SOD and GPx. It
was found that ACs doses less than 300 mg/day decreased levels of
MDA and isoprostane and increased SOD activity; however, significant
increase in GPx activity was determined by consuming ACs doses equalTa
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or more than 300 mg/day in participants. Administration of dietary ACs
reduced the levels of MDA, Ox-LDL, and isoprostane while increased
TAC level and SOD activity in unhealthy Subjects (Table 4).
3.11. Publication bias
On the basis of Begg and Mazumdar adjusted rank correlation test,
no evidence of publication bias was found for MDA (P = 0.103), Ox-
LDL (P = 0.805), isoprostane (P = 0.126), TAC (P = 0.392), SOD
(P = 0.063), and GPx (P = 0.881). In addition, Egger regression
asymmetry test showed no publication bias for MDA (P = 0.091), Ox-
LDL (P = 0.387), isoprostane (P = 0.501), TAC (P = 0.922), SOD
(P = 0.227), and GPx (P = 0.930).
4. Discussion
It has been determined that ACs have favorable antioxidative ac-
tivity, but it is varied from one anthocyanin compound to another. This
activity depends on the position and number of hydroxyl groups, degree
of glycosylation, and presence of donor electrons in their structure
(Miguel, 2011; Reis, Monteiro, de Souza Gomes, & do Carmo, M.M., da
Costa, G.V., Ribera, P.C., & Monteiro, M.C. , 2016).
Human interventional studies, in overall, have failed to confirm the
antioxidative effects of ACs. We conducted this meta-analysis in order
to find documental results on the effects of ACs administration on
markers of oxidative stress and antioxidative capacity. Our study re-
presented that lipid peroxidation decreased after consumption of ACs.
Researchers showed that there is an ATP-dependent process called
“revers cholesterol transport” in which cholesterol return from macro-
phages to the liver. It inhibits the production of Ox-LDL and therefore,
prevents the transformation of foam cell from macrophage. ACs are able
to act as electron receptors in complex I of mitochondrial respiratory
chain and promote ATP production (Skemiene, Liobikas, & Borutaite,
2015). They also activate AMP-activated protein kinases resulting in the
phosphorylation of acetyl COA carboxylase, which lead to increased
fatty acid metabolism (Forbes-Hernández et al., 2017; Yan & Zheng,
2017). These mechanisms warrant the reverse flow of cholesterol to the
liver.
ACs also inhibit the production of Ox-LDL by increasing the levels of
nuclear peroxisome proliferator-activator receptor γ (PPARγ) and
Table 2
Risk of bias assessment of included randomised controlled trials according to the Cochrane guidelines.
Study Random
sequence
generation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of
outcomeassessment
Incomplete
outcome data
Selective
outcome
reporting
Other
sources of
biasa
Overall
qualityb
Naruszewicz et al.
(2007)
U U H U L L L Fair
Basu et al. (2010) U U H U L L U Low
Broncel et al. (2010) U H H U U L U Low
Vidlar et al. (2010) L U U L L L L Good
Moazen et al. (2013) L U L L L L L Good
Puupponen-Pimiä
et al. (2013)
L U U L L L L Good
Riso et al. (2013) L L U U L L L Good
Basu et al. (2014) U U L L L L U Good
Soltani et al. (2014) L L L L L L L Good
Davinelli et al. (2015) U L L U L L L Good
Li et al. (2015) U U L L L L L Good
Park et al. (2015) U U L L L L L Good
Johnson et al. (2017) L U L L L L L Good
Riva et al. (2017) U U U L L L L Good
Nilsson et al. (2017) U U L L L L L Good
Xie et al. (2017) H H H U L L U Low
Espinosa-Moncada
et al. (2018)
L U L L L L L Good
Kim et al. (2018) L L L L L L U Good
Maeda-Yamamoto
et al. (2018)
L L L L L L L Good
Arevström et al.
(2019)
L U U L L L L Good
Chew et al. (2019) L L L L L U L Good
Guo et al. (2020) L L U U L L L Good
Terrazas et al. (2020) L L U U L L L Good
Abbreviations: L, low risk of bias; H, high risk of bias; U, unclear risk of bias
a Bias of study design, trial stopped early, extreme baseline imbalance, and fraudulent trial.
b “Good” if at least 4 domains were low risk of bias, “Fair” if 3 domains were low risk of bias, “Low” if less than 3 domains were low risk of bias.
Table 3
Summary of findings with the NutriGrade scoring system.
Outcome Effect size (95% CI) No. of participants (studies) Score Outcome quality
MDA −0.32 (−0.53, −0.11) 635 (18 RCTs) 8.5 High
Ox-LDL −0.50 (−1.00, 0.01) 352 (8 RCTs) 6 Moderate
Isoprostane −0.57 (−0.78, −0.36) 449 (13 RCTs) 7.25 Moderate
TAC 0.32 (0.08, 0.55) 325 (11 RCTs) 7 Moderate
SOD 0.37 (0.12, 0.62) 407 (8 RCTs) 7 Moderate
GPx 0.45 (0.0, 0.89) 331 (7 RCTs) 6 Moderate
Abbreviations: CI, confidence interval; GPx, glutathione peroxidase; MDA, malondialdehyde; Ox-LDL, oxidized low-density lipoprotein; RCTs, randomized controlled
trials; SOD, superoxide dismutase; TAC, total antioxidative capacity.
A.A. Fallah, et al. Journal of Functional Foods 68 (2020) 103912
6
downregulating the expression of CD36 gene in macrophages (Li,
Wang, Luo, Zhao, & Chen, 2017; Wang et al., 2012). Aviram et al.
(2004) showed that consumption of ACs increase serum paroxonase 1
activity, the major anti-atherosclerotic component of high-density li-
poprotein cholesterol (HDL-C), and support the blood cholesterol
cleaning property of these lipoproteins. By such aforementioned me-
chanisms, ACs reduce the production of cholesterol, low-density lipo-
protein cholesterol (LDL-C), and Ox-LDL hence reduce the levels of lipid
peroxidation markers like MDA and isoprostane (Arevström et al.,
2019; Skemiene et al., 2015; Takikawa, Inoue, Horio, & Tsuda, 2010). It
can be concluded that consumption of ACs-rich extracts reduces the risk
of atherosclerosis in human. Some studies reported that ACs inhibit the
production of antibodies against LDL-C, and prevent its degradation to
Ox-LDL (Takikawa et al., 2010; Weseler & Bast, 2012).
Inflammatory processes induce oxidative stress and reduce anti-
oxidative capacity. The nuclear factor κB (NF-κB) pathways play
Fig. 2. Forest plots of the effect of dietary anthocyanins on MDA (a), Ox-LDL (b), and isoprostane (c). For MDA meta-analysis performed without studies of Maeda-
Yamamoto et al. (2018) and Guo et al. (2020; anthocyanins dosage of 20 mg/day) and for Ox-LDL meta-analysis performed without study of Davinelli et al. (2015).
Fig. 3. Forest plot of the effect of dietary anthocyanins on total antioxidative capacity.
A.A. Fallah, et al. Journal of Functional Foods 68 (2020) 103912
7
important role in regulating inflammatory processes. These pathways,
activated by ROS, induce inflammation by increasing the gene expres-
sion of inflammatory markers. ACs can block NF-κB pathways by
trapping ROS, hence reducing inflammation and oxidative stress (Fallah
et al., 2020; Li et al., 2017; Miguel, 2011).
Plasminogen activator inhibitor-1 (PAI-1) is an adipocytokine as-
sociated with vascular inflammation and development of cardiovas-
cular and metabolic disorders. The ACs downregulated PAI-1 gene ex-
pression level, hence controled inflammation and oxidative stress
(Gomes et al., 2019).
ACs regulate the nitric-oxide synthase activity and inhibit the ac-
tivity of some oxidase enzymes that produce reactive oxygen molecules.
The hydroxyl groups in the structure of ACs reinforce the activity of
antioxidative enzymes like SOD (Ruel, Pomerleau, Couture, Lamarche,
& Couillard, 2005). ACs can be direct substrates for peroxidases, which
result in H2O2 deactivation, hence increase GPx activity (Broncel et al.,
2010). The mentioned mechanisms justify the enhancement of total
antioxidative capacity after consumption of ACs. It should be noted that
such effects are expected to be more pronounced in subjects with higher
levels of oxidative stress conditions. This was prominently observed in
our subgroup analysis on health status that ACs consumption have more
benefits for unhealthy subjects compared to healthy ones.
The in vitro and animal model studies demonstrated that the bio-
logical effects of ACs are mostly related to their antioxidative activities;
therefore, ACs can alleviate oxidative stress and enhance antioxidative
defense (Li et al., 2017; Miguel, 2011). Results of this meta-analysis did
not indicate dose-dependent effects of dietary ACs on markers of oxi-
dative stress and antioxidative capacity. In contrast, the dose-depen-
dent effects of ACs to ameliorate oxidative stress and enhance anti-
oxidative defense have been demonstrated in some in vitro and animal
model studies (Chen et al., 2019; Chen, Wang, Pan, Guo, & Chen, 2018;
Long, Gao, Sun, Liu, & Zhao-Wilson, 2009; Setiawan & Nadhil, 2019;
Yan & Zheng, 2017).
Results of this meta-analysis revealed that dietary ACs decreased the
levels of oxidative stress markers (MDA, isoprostane, and Ox-LDL) and
enhanced the markers of antioxidative capacity (TAC and SOD) only in
unhealthy subjects. But animal model studies demonstrated the bene-
ficial effects of ACs on markers of oxidative stress and antioxidative
defense in both healthy animals and animals with impaired health
(Bilanda et al., 2020; Li et al., 2019; Mahmoud, 2013; Noratto, Chew, &
Atienza, 2017; Sozański et al., 2019; Żary-Sikorska, Fotschki, Fotschki,
Wiczkowski, & Juśkiewicz, 2019).
It appears that administration of pure ACs or ACs-rich supplements,
as powerful antioxidants, are safe for most heathy and unhealthy in-
dividuals. Although occurrence of ACs adverse effects are uncommon,
minor cases of nausea, vomiting, constipation, diarrhea, or skin rash
was found following the administration of ACs (Basu et al., 2010;
Moazen et al., 2013; Yang et al., 2017).
Fig. 4. Forest plots of the effect of dietary anthocyanins on SOD (a) and GPx (b). For SOD and GPx meta-analyses performed without studies of Broncel et al. (2010)
and Riso et al. (2013), respectively.
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The limitations of current meta-analysis are as follows: (a) the used
trials administered various sources of ACs with different composition
and amount of other compounds; (b) the participants of used trials
varied in health status; (c) various methods were applied to determine
the levels of oxidative stress markers and activity of enzymes, which
may affect the results.
5. Conclusions
The results of current meta-analysis indicate that the administration
of dietary ACs reduced the levels of MDA, Ox-LDL, and isoprostane
while increased the level of TAC and activity of SOD and GPx.
Compared to healthy subjects, dietary ACs were more useful for un-
healthy subjects because of the significant decrease in levels of MDA,
Ox-LDL, and isoprostane and significant increase in TAC level and SOD
activity. We Suggest more clinical trials with various durations and
Table 4
Results of the effect of dietary anthocyanins on biomarkers of oxidative stress and antioxidative capacity based on subgroup analyses.
Outcome Variable No. of trials Effect size (95% CI) P value I2 (%) Q-statistics (P)
MDA Intervention duration
<8 weeksa 10 −0.45 (−0.70, −0.19) 0.001 31.1 0.160
≥8 weeksb 6 −0.35 (−0.71, 0.003) 0.052 35.8 0.168
Anthocyanins dosage
<300 mg/daya,b 11 −0.37 (−0.59, −0.15) 0.001 14.6 0.305
≥300 mg/day 5 −0.51 (−0.98, −0.04) 0.032 54.7 0.065
Health status
Healthya,b 7 −0.43 (−0.84, 0.05) 0.061 30 0.199
Unhealthy 9 −0.40 (−0.68, −0.12) 0.005 36 0.130
Ox-LDL Intervention duration
<8 weeksc 3 −0.20 (−0.70, 0.30) 0.422 42.5 0.176
≥8 weeks 4 −0.30 (−0.70, 0.09) 0.126 38.6 0.181
Anthocyanins dosage
<300 mg/dayc 3 −0.23 (−0.65, 0.20) 0.302 34.3 0.218
≥300 mg/day 4 −0.29 (−0.72, 0.15) 0.192 43.1 0.153
Health status
Healthy 3 0.03 (−0.33, 0.39) 0.881 0.0 0.920
Unhealthyc 4 −0.50 (−0.84, −0.16) 0.004 14.4 0.320
Isoprostane Intervention duration
<8 weeks 8 −0.75 (−1.02, −0.47) <0.001 0.0 0.839
≥8 weeks 5 −0.34 (−0.66, 0.01) 0.057 0.0 0.553
Anthocyanins dosage
<300 mg/day 10 −0.58 (−0.82, −0.34) <0.001 0.0 0.657
≥300 mg/day 3 −0.54 (−1.10, 0.02) 0.058 39.6 0.191
Health status
Healthy 6 −0.35 (−0.62, 0.10) 0.094 0.0 0.423
Unhealthy 7 −0.60 (−0.93, −0.28) <0.001 0.0 0.528
TAC Intervention duration
<8 weeks 8 0.37 (0.06, 0.68) 0.021 29.2 0.195
≥8 weeks 3 0.23 (−0.13, 0.56) 0.216 2.7 0.358
Anthocyanins dosage
<300 mg/day 9 0.29 (0.01, 0.60) 0.058 33.6 0.149
≥300 mg/day 2 0.40 (−0.01, 0.81) 0.056 0.0 0.841
Health status
Healthy 8 0.24 (−0.08, 0.56) 0.136 31.6 0.176
Unhealthy 3 0.47 (0.11, 0.82) 0.010 0.0 0.599
SOD Intervention duration
<8 weeks 2 0.08 (−0.37, 0.53) 0.732 0.0 0.742
≥8 weeksd 5 0.35 (0.10, 0.61) 0.006 0.0 0.534
Anthocyanins dosage
<300 mg/day 4 0.39 (0.11, 0.66) 0.005 0.0 0.428
≥300 mg/dayd 3 0.11 (−0.25, 0.48) 0.543 0.0 0.917
Health status
Healthy 3 0.18 (−0.18, 0.54) 0.335 0.0 0.770
Unhealthyd 4 0.35 (0.06, 0.64) 0.017 7 0.358
GPx Intervention duration
<8 weekse 1 1.03 (0.15, 1.90) 0.022 – –
≥8 weeks 5 0.52 (0.07, 0.97) 0.024 41.5 0.145
Anthocyanins dosage
<300 mg/day 3 0.35 (−0.37, 1.06) 0.344 56.7 0.099
≥300 mg/daye 3 0.79 (0.35, 1.22) <0.001 0.0 0.458
Health status
Healthy 3 0.69 (−0.02, 1.40) 0.058 53.4 0.117
Unhealthye 3 0.51 (−0.04, 1.07) 0.072 40.6 0.186
Abbreviations: CI, confidence interval; GPx, glutathione peroxidase; MDA, malondialdehyde; Ox-LDL, oxidized low-density lipoprotein; SOD, superoxide dismutase;
TAC, total antioxidative capacity.
a Analyses performed without study of Maeda-Yamamoto et al. (2018).
b Analyses performed without study of Guo et al. (2020; anthocyanins dosage of 20 mg/day).
c Analyses performed without study of Davinelli et al. (2015).
d Analyses performed without study of Broncel et al. (2010).
e Analyses performed without study of Riso et al. (2013).
A.A. Fallah, et al. Journal of Functional Foods 68 (2020) 103912
9
dosages in subjects with different health status to clarify the efficacy of
dietary ACs on markers of oxidative stress and antioxidative capacity.
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